Interim Clinical Commissioning Policy: Remdesivir for patients hospitalised due to COVID-19 (adults and adolescents 12 years and older)

Document first published:
Page updated:
Publication type:

Remdesivir is recommended to be available as a treatment option through routine commissioning for hospitalised adults and adolescents (aged 12 to less than 18 years and weighing at least 40 kg) with COVID-19 in accordance with the criteria set out in this document.


Published 24 February 2022.